OrthoPediatrics (KIDS) Reports Q2 Earnings: What Key Metrics Have to Say

Core Insights - OrthoPediatrics reported revenue of $61.08 million for the quarter ended June 2025, reflecting a year-over-year increase of 15.7% [1] - The company's EPS was -$0.11, an improvement from -$0.23 in the same quarter last year, with a surprise of +35.29% compared to the consensus estimate of -$0.17 [1] - The revenue fell short of the Zacks Consensus Estimate of $61.7 million, resulting in a surprise of -1% [1] Revenue Performance - Product sales in the Trauma and deformity category reached $41.67 million, below the three-analyst average estimate of $44.58 million, marking a year-over-year increase of 10.3% [4] - Sales in the Sports medicine/other category were $0.91 million, significantly lower than the $1.18 million average estimate, representing a year-over-year decline of 32.9% [4] - Scoliosis product sales amounted to $18.52 million, exceeding the average estimate of $15.95 million, with a year-over-year increase of 35.4% [4] Stock Performance - Over the past month, OrthoPediatrics shares have returned -3.3%, contrasting with the Zacks S&P 500 composite's +1% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [3]